$0.510000
-0.04-6.58%
At Close: -
$0.519000
0.00901.76%
After Hours: 7:43 PM EDT
15 minutes delayed
Comments
Loading...
Seelos Therapeutics
SEELNASDAQ
Seelos Therapeutics (NASDAQ:SEEL) Stock, Analyst Ratings, Price Targets, Forecasts
Seelos Therapeutics Inc has a consensus price target of $4.25 based on the ratings of 6 analysts. The high is $8 issued by Roth Capital on September 27, 2021. The low is $1 issued by Benchmark on September 21, 2023. The 3 most-recent analyst ratings were released by Benchmark, Cantor Fitzgerald, and Cantor Fitzgerald on September 21, 2023, August 22, 2023, and August 15, 2023, respectively. With an average price target of $1.67 between Benchmark, Cantor Fitzgerald, and Cantor Fitzgerald, there's an implied 221.13% upside for Seelos Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Benchmark
BTIG
B. Riley Securities
Roth Capital
1calculated from analyst ratings
Analyst Ratings for Seelos Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 09/22/2023 | Buy Now | — | Guggenheim | Yatin Suneja | — | Downgrade | Buy → Neutral | Get Alert |
| 09/21/2023 | Buy Now | 92.68% | Benchmark | Bruce Jackson | $960 → $240 | Maintains | Speculative Buy | Get Alert |
| 09/21/2023 | Buy Now | — | Guggenheim | Yatin Suneja | — | Downgrade | Buy → Neutral | Get Alert |
| 09/21/2023 | Buy Now | — | Cantor Fitzgerald | Charles Duncan | — | Downgrade | Overweight → Neutral | Get Alert |
| 08/22/2023 | Buy Now | 285.36% | Cantor Fitzgerald | Charles Duncan | → $480 | Reiterates | Overweight → Overweight | Get Alert |
| 08/15/2023 | Buy Now | 285.36% | Cantor Fitzgerald | Charles Duncan | → $480 | Reiterates | Overweight → Overweight | Get Alert |
| 06/23/2023 | Buy Now | 285.36% | Cantor Fitzgerald | Charles Duncan | → $480 | Reiterates | Overweight → Overweight | Get Alert |
| 06/23/2023 | Buy Now | 670.71% | Benchmark | Bruce Jackson | $960 → $960 | Reiterates | Speculative Buy → Speculative Buy | Get Alert |
| 05/16/2023 | Buy Now | 285.36% | Cantor Fitzgerald | Charles Duncan | $720 → $480 | Maintains | Overweight | Get Alert |
| 05/15/2023 | Buy Now | 670.71% | BTIG | Robert Hazlett | $2640 → $960 | Maintains | Buy | Get Alert |
| 03/30/2023 | Buy Now | 2019.46% | BTIG | Robert Hazlett | → $2640 | Maintains | Buy | Get Alert |
| 03/24/2023 | Buy Now | 670.71% | Benchmark | Bruce Jackson | $1440 → $960 | Maintains | Buy | Get Alert |
| 02/13/2023 | Buy Now | 2212.14% | BTIG | Robert Hazlett | $2880 → $2880 | Maintains | Buy | Get Alert |
| 04/28/2022 | Buy Now | 2212.14% | BTIG | Robert Hazlett | → $2880 | Maintains | Buy | Get Alert |
| 03/14/2022 | Buy Now | 670.71% | B. Riley Securities | Mayank Mamtani | $1440 → $960 | Maintains | Buy | Get Alert |
| 03/08/2022 | Buy Now | 478.03% | Cantor Fitzgerald | Charles Duncan | $1200 → $720 | Maintains | Overweight | Get Alert |
| 09/27/2021 | Buy Now | 1441.43% | Roth Capital | Jonathan Aschoff | $600 → $1920 | Upgrade | Neutral → Buy | Get Alert |
| 08/10/2021 | Buy Now | 381.7% | Roth Capital | Jonathan Aschoff | $960 → $600 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for Seelos Therapeutics (SEEL) stock?
The latest price target for Seelos Therapeutics (NASDAQ:SEEL) was reported by Guggenheim on September 22, 2023. The analyst firm set a price target for $0.00 expecting SEEL to fall to within 12 months (a possible -100.00% downside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Seelos Therapeutics (SEEL)?
The latest analyst rating for Seelos Therapeutics (NASDAQ:SEEL) was provided by Guggenheim, and Seelos Therapeutics downgraded their neutral rating.
When was the last upgrade for Seelos Therapeutics (SEEL)?
The last upgrade for Seelos Therapeutics Inc happened on September 27, 2021 when Roth Capital raised their price target to $8. Roth Capital previously had a neutral for Seelos Therapeutics Inc.
When was the last downgrade for Seelos Therapeutics (SEEL)?
The last downgrade for Seelos Therapeutics Inc happened on September 22, 2023 when Guggenheim changed their price target from N/A to N/A for Seelos Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Seelos Therapeutics (SEEL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Seelos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Seelos Therapeutics was filed on September 22, 2023 so you should expect the next rating to be made available sometime around September 22, 2024.
Is the Analyst Rating Seelos Therapeutics (SEEL) correct?
While ratings are subjective and will change, the latest Seelos Therapeutics (SEEL) rating was a downgraded with a price target of $0.00 to $0.00. The current price Seelos Therapeutics (SEEL) is trading at is $0.52, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.